Amongst sufferers with gastric/gastroesophageal junction (G/GEJ) adenocarcinoma that’s resectable, or detachable by surgical procedure the mixture of the anti-PD-L1 monoclonal antibody Imfinzi (durvalumab) with the FLOT (5-fluorouracil-leucovorin-oxaliplatin-docetaxel) chemotherapy routine was related to a major and clinically significant enchancment in general survival, or the time sufferers stay after therapy, when in comparison with placebo plus FLOT.
These findings, which have been no matter pathological standing, have been shared in a presentation of information from the part 3 MATTERHORN trial on the 2025 European Society for Medical Oncology (ESMO) Congress in Berlin, Germany.
With a knowledge cutoff date of Sept. 1, 2025, the ultimate general survival evaluation of the intention-to-treat inhabitants yielded a hazard ratio (HR) of 0.78 evaluating the investigational arm with the management arm, with median OS not reached in both arm.
Glossary
Total Survival (OS): The size of time from the beginning of therapy or prognosis that sufferers in a research are nonetheless alive.
Occasion-Free Survival (EFS): The size of time sufferers stay alive with out sure occasions occurring, such because the most cancers coming again, progressing, or loss of life from any trigger.
Pathological Full Response (pCR): Which means when the tissue eliminated throughout surgical procedure is examined underneath a microscope, no indicators of invasive most cancers are discovered.
“The general survival outcomes of the MATTERHORN research strongly help using Imfinzi plus chemotherapy with FLOT as a brand new international normal of look after sufferers with localized, [resectable, G/GEJ] adenocarcinoma,” stated Dr. Josep Tabernero, professor of medication, head, Division of Medical Oncology, Vall d’Hebron College Hospital, and director of Vall d’Hebron Institute of Oncology, Barcelona, Spain, in his presentation.
Moreover, a survival evaluation stratified by demographic and scientific traits confirmed that OS enchancment was constant throughout most key subgroups. Notably, the same enchancment in OS was achieved no matter PD-L1 standing. In sufferers who have been PD-L1-positive, the HR was 0.79, and the HR was 0.79 in sufferers who have been PD-L1-negative, even demonstrating an identical HRs throughout teams.
Extra findings reported included an enchancment in event-free survival (EFS), the research’s main finish level, amongst sufferers with any diploma of pathological response and no matter pathological nodal standing on the time of the information cutoff on Dec. 20, 2024.
What Are the Examine Design and Affected person Traits?
The part 3 MATTERHORN trial is a world, randomized, double-blind, placebo-controlled research evaluating the efficacy of neoadjuvant-adjuvant durvalumab plus FLOT chemotherapy. The research’s main finish level is EFS; key secondary finish factors embody OS and pathological full response (pCR).
The research inhabitants consists of 948 sufferers with localized G/GEJ adenocarcinoma who have been treatment-naive upon enrollment. Sufferers have been enrolled from throughout Asia, Europe, North America and South America; of be aware, in accordance Tabernero, is that 20% of sufferers have been from Asia. Sufferers have been stratified by geographical area, scientific lymph node standing and PD-L1 expression.
For therapy, sufferers have been randomly assigned to obtain both the Imfinzi and FLOT mixture or placebo plus FLOT (474 sufferers, each arms) within the neoadjuvant setting. Right here, sufferers acquired their 1500 mg of their assigned therapy plus FLOT for 2 cycles earlier than present process surgical resection 4 to eight weeks after their final dose. Following surgical resection restoration, sufferers acquired 1500 mg of durvalumab or placebo as adjuvant remedy for as much as one 12 months.
What Trial Knowledge Have Been Beforehand Reported?
In 2023, interim outcomes with a knowledge cutoff on Feb. 1, 2023 prompt a major and clinically significant profit in pCR and near-PCR, with response charges of 27% and 14% noticed within the investigational and management arms, respectively. Subsequent, earlier in 2025, outcomes of a main finish level evaluation revealed in The New England Journal of Medication revealed a two-year EFS price of 67.4% within the investigational arm versus 58.5% within the management arm. A constant and manageable security profile between arms was depicted in each stories.
Using on the favorable efficacy and security tendencies noticed in earlier analyses, this most up-to-date readout highlights the potential of durvalumab and FLOT to turn into a brand new perioperative therapy possibility for sufferers.
References
- “Remaining general survival (OS) and the affiliation of pathological outcomes with event-free survival (EFS) in MATTERHORN: A randomised, part III research of durvalumab (D) plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric / gastroesophageal junction (G / GEJ) adenocarcinoma.” by Dr. Josep Tabernero. Offered at: ESMO 2025 Congress; October 17–20, 2025; Berlin, Germany. Summary LBA81.
- “Assessing durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction most cancers;”
https://clinicaltrials.gov/research/NCT04592913
For extra information on most cancers updates, analysis and training,
